Acura is a specialty pharmaceutical company engaged in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing the Company’s proprietary, tamper-resistant AVERSION® and IMPEDE® Technology platforms. Acura’s products and product candidates are based on widely-used commercial products and do not alter the safety and efficacy of the active pharmaceutical ingredients that are intended to effectively relieve pain while simultaneously discouraging common methods of opioid product tampering, including:
- Intravenous injection by forming a viscous gelatinous mixture when tablets and capsules are dissolved in solvents suitable for injection
- Nasal snorting by inducing disliked nasal discomfort when tablets or capsules are crushed and snorted
Acura’s innovative AVERSION® Technology platform has been successfully utilized in developing multiple abuse deterrent opioid analgesic product candidates. The first product commercialized utilizing AVERSION® Technology is OXECTA® (oxycodone hydrochloride) Tablets CII and is being commercialized by Pfizer.
In addition, Acura has seven other abuse deterrent products in development utilizing AVERSION® Technology:
- Hydrocodone bitartrate/acetaminophen tablets
- Oxycodone HCl/acetaminophen tablets
- Hydromorphone tablets
- Morphine tablets
- Oxymorphone tablets
- Tramadol tablets
- Methadone tablets
The Company’s IMPEDE® Technology platform is an advanced polymer matrix that is used in NEXAFED®, Acura’s pseudoephedrine (PSE) tablet product, to limit or disrupt the extraction of PSE from tablets for conversion into the illicit drug methamphetamine.